<DOC>
	<DOCNO>NCT02972450</DOCNO>
	<brief_summary>EVHA T01 Phase IIb randomise therapeutic HIV vaccine trial individual start antiretrovirals primary chronic infection . HIV+ participant randomise receive active vaccine placebo .</brief_summary>
	<brief_title>An HIV Vaccine Trial Individuals Who Started ART During Primary Chronic Infection</brief_title>
	<detailed_description>EVHA T01 international , multicentre , double-blind study two-arm prospective 1:1 randomisation compare active vaccine placebo control . Randomisation stratify accord stage infection antiretroviral therapy ( cART ) commence either primary infection chronic infection . Screening take place 6 week prior randomisation . Eligible participant enrol week 0 randomise either vaccine placebo . They continue cART 12 week vaccination period 12 week beyond . Treatment interrupt resumed viral load rebound 10,000 copies/ml , CD4 fall 350 less cells/mm3 , evidence disease progression , complete 24 week interruption .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Aged 18 65 year old 2 . Weight &gt; 50kg 3 . Able give write informed consent include consent longterm followup 4 . Nadir CD4 count &gt; 300 cells/mm3 5 . CD4 count screen &gt; 600 cells/mm3 6 . Started cART 2009 cART least one year . 7 . Viral load le 50 copies/ml screening . 8 . Willing interrupt cART 24weeks 9 . If sexually active , willing use reliable method reduce risk transmission sexual partner treatment interruption ( could include PrEP sexual partner ) 10 . If heterosexually active female able child , use highly effective method contraception partner ( combined oral contraceptive pill ; injectable implanted contraceptive ; IUD/IUS ; physiological anatomical sterility ( self partner ) 14 day prior first vaccination 4 month last , willing undergo urine pregnancy test prior vaccination 11 . If heterosexually active male able child , use effective method contraception partner first day vaccination 4 month last vaccination 12 . Willing avoid vaccine within 4 week schedule study vaccine 13 . Willing able comply visit schedule provide blood sample 14 . Participants medical insurance National Healthcare System 1 . Pregnant lactate 2 . HIV2 infection ( either isolate associated HIV1 ) 3 . VL &gt; 200 copies/ml 2 occasion 12 month prior screen 4 . Previous interruption cART 5 . Previous virological failure define loss virological suppression presence resistant mutation 6 . Haemoglobin ( Hb &lt; 12g/dL male , &lt; 11g/dL female ) 7 . Concomitant previous condition preclude vaccination . 8 . History experimental vaccination HIV 9 . Previous treatment chemotherapy ( except chemotherapy inject skin lesion Kaposi 's Sarcoma ) 10 . Treatment systemic corticoid immunosuppressive agent ongoing previous 12 week randomisation trial 11 . Administration inactivate vaccine within 30 day live vaccine within 60 day prior randomisation 12 . Presence skin condition mark precludes inspection administration site 13 . History cancer ( except basal cellular skin carcinoma Kaposi 's sarcoma ) 14 . History cardiovascular disease ( angina , myocardial infarction , transient ischemic attack , stroke ) ; participant control blood pressure eligible . 15 . History clinical autoimmune disease reactive arthritis 16 . Ongoing cardiac , pulmonary ( exclude mild asthma ) , thyroid , renal neurological ( peripheral central ) diseases 17 . Participating another biomedical research study within 30 day randomisation . 18 . Known hypersensitivity component vaccine formulation use trial include aminoglycosides egg severe multiple allergy drug pharmaceutical agent . 19 . Liver disease include hepatitis B ( surface antigen positive ) hepatitis C ( antigen PCR positive ) 20 . A clinically significant abnormality ECG 21 . History severe local general reaction vaccination define 1. local : extensive , indurated redness swell involve arm , resolve within 72 hour 2. general : fever &gt; = 39.5oC within 48 hour ; anaphylaxis ; bronchospasm ; laryngeal oedema ; collapse ; convulsion encephalopathy within 72 hour 22 . Grade 2 bad routine laboratory parameter ( see Appendix 4 definition ) . Hyperbilirubinaemia consider exclusion criterion confirm conjugate bilirubinaemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>